PSA screening reduces deaths by a fifth
The pro-PSA testing camp has been given a boost with a large randomised study showing it could reduce prostate cancer deaths by about a fifth.
However, the authors acknowledge over-diagnosis is a problem, with roughly 40% of positive tests proving to be false.
They conclude that introducing routine PSA screening now would be premature.
Despite the survival advantage, Professor Ian Olver, CEO of Cancer Council Australia, agrees the results